Cilta-Cel Allows for Treatment-Free Period in Early R/R Multiple ...
FDA approved ciltacabtagene autoleucel (cilta-cel) for relapsed/refractory multiple myeloma, showing a 59% risk reduction in disease progression or death vs standard care in the CARTITUDE-4 trial. Despite early OS concerns, cilta-cel's benefits outweigh risks, offering a treatment-free period post-administration. Accessibility and logistics remain challenges.
Related Clinical Trials
Reference News
FDA approved ciltacabtagene autoleucel (cilta-cel) for relapsed/refractory multiple myeloma, showing a 59% risk reduction in disease progression or death vs standard care in the CARTITUDE-4 trial. Despite early OS concerns, cilta-cel's benefits outweigh risks, offering a treatment-free period post-administration. Accessibility and logistics remain challenges.
FDA approved ciltacabtagene autoleucel (Carvykti) for relapsed/refractory multiple myeloma patients, based on CARTITUDE-4 study showing 59% reduced risk of disease progression or death. Median PFS not reached with cilta-cel vs 11.8 months with standard care. Cilta-cel showed 75.9% 12-month PFS rate, 73.1% CR or better rate, and 84.6% ORR. Safety profile includes grade 3/4 toxicities and boxed warnings for CRS, ICANS, and secondary malignancies.